CM
ESPR

Crestline Management’s Esperion Therapeutics ESPR Stock Holding History

Crestline Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-28,745
Closed -$63.2K – 208
2024
Q4 		$63.2K Buy
+28,745
New +$67.1K ﹤0.01% 703
2018
Q3 		– Sell
-44,224
Closed -$1.73M – 175
2018
Q2 		$1.73M Buy
+44,224
New +$2.23M 0.18% 157
2017
Q4 		– Sell
-26,350
Closed -$1.32M – 173
2017
Q3 		$1.32M Sell
26,350
-14,616
-36% -$705K 0.18% 89
2017
Q2 		$1.9M Buy
40,966
+13,566
+50% +$499K 0.25% 45
2017
Q1 		$967K Buy
+27,400
New +$627K 0.18% 55

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Crestline Management's ESPR Position: Q1 2025 in Review

Crestline Management sold out of Esperion Therapeutics (ESPR) in Q1 2025, closing a stake of 28,745 shares — an estimated $63.2K sold.

Crestline Management first reported a position in ESPR in Q1 2017 and held it in 5 quarters. The position peaked at $1.9M in Q2 2017. 186 funds tracked by Wall St. Rank hold ESPR as of Q1 2025.

  • Crestline Management reported no remaining Esperion Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 28,745 Esperion Therapeutics shares in Q1 2025, an estimated $63.2K.
  • Crestline Management first reported a position in Esperion Therapeutics in Q1 2017 and held it in 5 quarters.
  • Crestline Management's Esperion Therapeutics position peaked at $1.9M in Q2 2017.
  • 186 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.